The launch of the GMP PSXi013 iPSC Master Cell Bank marks a pivotal moment in Pluristyx's ongoing mission to accelerate the development of stem cell therapies. By providing a high-quality, low-passage ...
Small biotechs in early development of cell therapies are often surprised by the strictness of commercial manufacturing standards. That’s the view of Luděk Sojka, PhD, CEO of contract developer and ...
Pheast Therapeutics is using a platform-based approach to scaling manufacturing for its anti-CD24 checkpoint inhibitor, PHST001. By compressing the chemistry, manufacturing, and control (CMC) steps ...
GentiBio, Inc., an emerging biotherapeutics company developing best-in-class engineered regulatory T cells programmed to treat autoimmune, alloimmune, autoinflammatory, and allergic diseases, and ...
HOPEWELL, N.J., Aug. 11, 2025 /PRNewswire/ -- ProBio, a leading contract development and manufacturing organization (CDMO) specializing in gene and cell therapy, today announced the launch of its cGMP ...
SEONGDONG-GU, SEOUL, SOUTH KOREA, January 5, 2023 / EINPresswire.com / -- MDimune Inc., a Korean biotech company developing BioDrone™ platform technology based on cell-derived vesicles (CDVs), ...
VANCOUVER, British Columbia, Jan. 21, 2025 (GLOBE NEWSWIRE) -- HYTN Innovations Inc. (CSE: HYTN, FSE: 85W0, OTC PINK: HYTNF) (“HYTN” or the “Company”), a company specializing in pharmaceutical-grade ...
NEW YORK, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (PBM) ("Psyence Biomed" or the "Company") is pleased to provide an update on its previously-announced pending strategic acquisition ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback